Cantor Fitzgerald Weighs in on Pharvaris FY2026 Earnings

Pharvaris (NASDAQ:PHVS) – Research analysts at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Pharvaris in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst S. Seedhouse expects that the company will post earnings of ($3.75) per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $25.00 target price on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share.

Pharvaris (NASDAQ:PHVS) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.09).

Other equities research analysts have also issued research reports about the stock. Wedbush restated an “outperform” rating and issued a $27.00 price target on shares of Pharvaris in a report on Thursday, June 5th. Guggenheim began coverage on shares of Pharvaris in a report on Wednesday. They set a “buy” rating and a $32.00 price objective on the stock. Five analysts have rated the stock with a buy rating, According to MarketBeat, Pharvaris currently has a consensus rating of “Buy” and an average price target of $36.20.

Pharvaris Trading Up 0.5%

Shares of PHVS opened at $18.12 on Wednesday. The firm has a fifty day moving average price of $15.70 and a 200-day moving average price of $17.00. The firm has a market capitalization of $947.49 million, a P/E ratio of -6.47 and a beta of -2.86. Pharvaris has a 12-month low of $11.51 and a 12-month high of $25.50.

Institutional Trading of Pharvaris

Several hedge funds have recently made changes to their positions in PHVS. Deutsche Bank AG increased its stake in shares of Pharvaris by 13.0% during the fourth quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock worth $348,000 after buying an additional 2,087 shares during the period. JPMorgan Chase & Co. grew its holdings in Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after acquiring an additional 2,847 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Pharvaris in the 4th quarter valued at approximately $64,000. Legal & General Group Plc raised its holdings in shares of Pharvaris by 11.2% in the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock valued at $189,000 after purchasing an additional 994 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company’s stock valued at $1,222,000 after purchasing an additional 14,838 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.